Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 14/20 | 0.59 |
| ▸ | F2 | P00734 | 4/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.44 |
| ▸ | PLG | P00747 | 4/20 | 0.44 |
| ▸ | KLK1 | P06870 | 3/20 | 0.44 |
| ▸ | PLAT | P00750 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7856857 | 0.85 | PLAU (0.83) | PLAUF2PRSS1PLGKLK1 | |
| SCHEMBL7334796 | 0.84 | PLAU (0.54) | PLAUF2PRSS1PLGKLK1 | |
| Trifluoroacetic Acid SCHEMBL7337301 | 0.83 | PLAU (0.64) | PLAUF2PRSS1PLGKLK1 | |
| Trifluoroacetic Acid SCHEMBL7342930 | 0.83 | PLAU (0.61) | PLAUF2PRSS1PLGKLK1 | |
| Trifluoroacetic Acid SCHEMBL7343140 | 0.83 | PLAU (0.61) | PLAUF2PRSS1PLGKLK1 | |
| Trifluoroacetic Acid SCHEMBL7335260 | 0.82 | PLAU (0.53) | PLAUF2PRSS1PLGKLK1 | |
| Trifluoroacetic Acid SCHEMBL7337591 | 0.79 | PLG (0.51) | PLAUF2PRSS1PLGKLK1 | |
| Trifluoroacetic Acid SCHEMBL7334801 | 0.79 | KDM4E (0.36) | PLAUCYP1A2CYP2C9CYP2C19 | |
| Trifluoroacetic Acid SCHEMBL7337885 | 0.79 | PLAU (0.55) | PLAUF2PRSS1PLGKLK1 | |
| Trifluoroacetic Acid SCHEMBL7456773 | 0.78 | PLAU (0.70) | PLAUF2PRSS1PLGKLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6423689-B1 | Peptidyl calcium channel blockers | WARNER-LAMBERT COMPANY | 2002-07-23 | — | — | US | claimed |
| US-20010049374-A1 | Urokinase inhibitors | STEELE ANDREW W (US) | 2001-12-06 | — | — | US | claimed |
| EP-1000018-A2 | UROKINASE INHIBITORS | Abbott Laboratories (US) | 2000-05-17 | — | — | EP | claimed |
| WO-1999005096-A2 | UROKINASE INHIBITORS | ABBOTT LABORATORIES (US) | 1999-02-04 | — | — | WO | claimed |
| US-6423689-B1 | Peptidyl calcium channel blockers | WARNER-LAMBERT COMPANY | 2002-07-23 | — | — | US | disclosed |
| US-20010049374-A1 | Urokinase inhibitors | STEELE ANDREW W (US) | 2001-12-06 | — | — | US | disclosed |
| US-6284796-B1 | NAPHTHAMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-09-04 | — | — | US | disclosed |
| US-6258822-B1 | ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-07-10 | — | — | US | disclosed |
| US-6090828-A | ARTHERIOSCLEROSIS | REITZ DAVID B (US) | 2000-07-18 | — | — | US | disclosed |
| US-5451593-A | Method of using 5-arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of a glaucoma disorder | G. D. SEARLE & CO. (US) | 1995-09-19 | — | — | US | disclosed |
| US-5451591-A | Method of using 5-arylheteroarylalkyl-1,3 5-trisubstituted-1,24-triazole compounds for treatment of circulatory disorders | G. D. SEARLE & CO. (US) | 1995-09-19 | — | — | US | disclosed |
| US-5196537-A | Angiotensin/II/ antagonists; hypotensive agents | G. D. SEARLE & CO. (US) | 1993-03-23 | — | — | US | disclosed |
| EP-0504888-A1 | 5-Arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders | G.D. Searle & Co. (US) | 1992-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | SERPINE1, PLAU, SERPINB1 | PLAU 2/4885F2 38/4885PRSS1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.